CMPX — Compass Therapeutics, Inc.
Company context · prepared 2026-10-17 · company sweep 2026-10-17 · USD · framework v6.2.0
How to read this. Written for a curious reader with little or no background in science, medicine, the drug industry or finance. General terms are explained once in the glossary. All money figures are in US dollars (USD). Every fact carries one of three tags.
[VERIFIED — source]means a primary source confirmed it, and the source is named.[UNVERIFIED]means it could not be confirmed.[WEB ESTIMATE — source, date]means it is a third-party figure or a labelled model.Program analyses for this company are the sub-folders listed in C.2.
Why the company tier was re-run. The previous company sweep was dated 2026-08-19, 59 days
before this one. 02-connectors.md § Company-sweep currency allows reuse for 30 days only. A
material event also landed in the press feed since then: the FDA feedback of 2026-09-22 (C.7). So
every company-tier row below was called again on 2026-10-17. This version replaces the 5.10.3
document and keeps its corrections and audit trails, marked where they still apply.
C.0 Company-tier coverage — CLEARED
Every mandatory company-tier row was called. The regulatory tier is not part of this table. It is
conditional on a regulatory catalyst (02-connectors.md § Regulatory tier), and the catalyst
analysed under this ticker is a congress presentation. No marketing application has been filed.
| Tool | State | Note / verbatim error |
|---|---|---|
BPIQ fetch_company_info | CALLED | finance_updated_at 2026-06-30, so cash and burn are quarter-end figures. last_price 0.86 and previous_close 0.90 match the price cache’s 2026-10-16 and 2026-10-15 closes. market_cap and max_52_week_position reconcile this time (C.8 row 1). enterprise_value does not (C.8 row 2). |
BPIQ fetch_company_drugs | CALLED | 6 rows, every one in C.2. Three carry has_catalyst: true. Names stay dirty ("Tovecimig (CTX-009) …" has a double space), so every row is keyed on the integer id. The tovecimig row’s note gained a 2026-09-22 entry: “FDA advised survival-benefit trial before BLA; company will further engage FDA. ESMO data Oct 24, 2026.” |
BPIQ fetch_company_historical_catalysts | CALLED | Called as fetch_all_historical_catalysts filtered to tickers: ["CMPX"], the connector’s current name for this row. 8 rows, one new (2026-09-22). Every row was re-checked against the price cache, which did not exist at the last sweep. Several BPIQ move fields do not reproduce from the cache (C.7 and C.8 row 3). |
BPIQ fetch_company_options_data | CALLED | date_updated 2026-10-17, 9 expiries. No strike sits at the $0.86 spot; the nearest are $0.50 and $1.00. Both implied-volatility artifacts are present. See C.6. |
BPIQ fetch_company_insider_transactions | CALLED | Returned no rows on three attempts (immediate, retry, and again about ten minutes later), with no error. Two Form 4 filings exist in the window (EDGAR, 2026-09-25 and 2026-10-02). So the silent empty-result bug 02-connectors.md records on TLSA and CNTB now fires on this ticker. It did not fire on 2026-08-19, when the same call returned 113 rows. Insider flow in C.5 is read from EDGAR. |
BPIQ fetch_company_press_releases | CALLED | 221 items, the newest dated 2026-10-14. Used for the same-day checks in C.7 and the delivery record in C.1a. Two GlobeNewswire originals (2026-09-22 and 2026-10-14) returned HTTP 403 to a direct fetch. The 2026-09-22 text was read from its SEC copy instead (8-K exhibit 99.1). |
optional BPIQ fetch_company_hedge_fund_holdings | CALLED | 19 blocks, 2022Q2 to 2026Q3. No block is newer than at the last sweep. Labels confirmed as filing quarters against the price cache (C.8 row 6). |
optional BPIQ fetch_company_earnings_transcript | NOT CALLED | Optional row. The latest call (second quarter, 2026-08-06) predates the FDA feedback, so it could not speak to the event that moved the shares. |
EDGAR submissions | CALLED | CIK 0001738021. Filings since 2026-08-19: an 8-K on 2026-09-22 (items 7.01 and 9.01, the FDA update) and two Form 4s. No 8-K item 3.01 (a listing-deficiency notice), no proxy proposing a reverse split, and no new S-3 or 424B5 (a share sale). |
EDGAR XBRL companyconcept (dei:EntityCommonStockSharesOutstanding) | CALLED | 180,087,915 shares at 2026-07-28, from the 10-Q filed 2026-08-06. No later filing reports a count. The companion companyfacts call supplied cash, marketable securities, operating cash flow, options outstanding and total liabilities (C.3, C.4). |
FINRA consolidatedShortInterest | CALLED | Settlements 2026-07-31 to 2026-09-30 returned. The newest is 2026-09-30: 40,357,710 shares short, average daily volume 6,449,901, days-to-cover 6.26. The 2026-10-15 settlement returned empty, which is FINRA’s normal two-week publication lag. |
| optional Yahoo options chain | NOT CALLED | Optional row. BPIQ’s chain is dated the sweep day and already shows that no strike sits at spot, which settles C.6 by itself. (Yahoo’s daily chart was called once, as a price cross-check. That is not this row. See C.8 row 4.) |
C.1 What the company is
Compass Therapeutics is a clinical-stage cancer company in Boston, Massachusetts, founded in 2014.
It makes antibody drugs, which are proteins engineered to stick to a chosen target on or around a
tumour [VERIFIED — BPIQ fetch_company_info 2026-10-17]. It runs four molecules across the six
pipeline rows in C.2. It has no approved product and no product revenue. Its 2025 revenue was nil,
and its only past revenue was $850 thousand of licence income in 2024 from its Chinese partner
[VERIFIED — Form 10-K for 2025, filed 2026-03-05].
In practice it is close to a single-asset company. One molecule, tovecimig (also called CTX-009), carries the only finished randomised trial and the only planned marketing application. On 2026-09-22 the FDA recommended a new trial showing a survival benefit before that application is filed (C.7). The shares now trade at about the company’s cash (C.4). That means the market currently assigns close to nothing to tovecimig or to the three earlier molecules.
Tovecimig is licensed, not owned. Compass took an exclusive global licence, excluding South Korea,
from the South Korean company ABL Bio in November 2018. ABL Bio is owed tiered single-digit
royalties on net sales and up to $96 million of development and regulatory milestones plus up to
$303 million of commercial milestones in cancer [VERIFIED — Form 10-Q filed 2026-08-06, note 11].
South Korean rights sit with Handok. Compass out-licensed China to Elpiscience
[VERIFIED — Form 10-K for 2025]. Named correction: the 5.10.3 version called these licence
terms an unverified web estimate. They are now read from the filings, and they match.
C.1a Delivery record and capabilities
Program documents cite this section: A.5 uses the first two rows, M.4 the manufacturing rows and
B.4d the last two. The milestone rows are read from the BPIQ note field (a dated log of the
company’s own guidance) and checked against the press feed and EDGAR. Search date 2026-10-17.
| Item | Finding | Source / tag |
|---|---|---|
| Milestones met | (1) COMPANION-002 enrolment completed 2024-08-06. (2) CTX-10726 IND filing guided for the fourth quarter of 2025; cleared by 2026-03-05 (an IND, an investigational new drug application, is the FDA filing that lets a trial start). (3) CTX-8371 Phase 1 data guided for the first half of 2026; poster at ASCO in May 2026. (4) FDA feedback on COMPANION-002 guided for the third quarter of 2026; announced 2026-09-22. (5) ESMO oral slot announced 2026-07-17 for 2026-10-24, unchanged since. | [VERIFIED — BPIQ fetch_company_drugs note field 2026-10-17; EDGAR 8-K 2026-09-22] |
| Milestones missed or moved | (1) COMPANION-002 topline guided “by the end of Q1 2025”; reported 2025-04-01, one day late. (2) Overall-survival data guided for the first quarter of 2026; reported 2026-04-27, about four weeks late. (3) The marketing application (BLA, Biologics License Application) was guided for the second half of 2026; it has not been filed, and the FDA has recommended a survival trial first. Secondary reports say the company now targets the first quarter of 2027. That date is not in the 2026-09-22 release or any filing. (4) The CTX-471 Phase 2 start has been re-guided five times (second half of 2025, then Q1 2026, mid-2026, second half of 2026, Q3 2026). The trial (NCT07684170) is registered but was “not yet recruiting” on 2026-10-17, after the Q3 deadline passed. (5) CTX-10726’s first patient was guided for the first quarter of 2026; the registry shows a start on 2026-05-28. | [VERIFIED — BPIQ note field 2026-10-17; CT.gov NCT07684170 and NCT07419841, read 2026-10-17]; Q1 2027 BLA [WEB ESTIMATE — Stocktwits and aggregated coverage, 2026-09-23] |
| Own manufacturing sites | None. “We do not currently own or operate manufacturing facilities for the production of clinical quantities of our product candidates.” | [VERIFIED — Form 10-K for 2025, Business, Manufacturing] |
| Contract manufacturers | Third-party contract development and manufacturing organisations (CDMOs). None is named in the 10-K, the 10-Q or the press feed. The second-quarter 10-Q shows $7.5 million of accrued manufacturing expense, mostly for tovecimig, and lists “registration and validation batches” among manufacturing costs. No public record names the site as of 2026-10-17. | [VERIFIED — Form 10-K for 2025; Form 10-Q filed 2026-08-06] |
| Launch experience and sales force | No drug launched. No sales force. 39 employees at 2025-12-31, 25 of them in research and clinical work. A Chief Commercial Officer joined 2026-01-05. A new hire received 200,000 inducement options at $0.86 on 2026-10-14. | [VERIFIED — Form 10-K for 2025; press feed 2026-01-05]; 2026-10-14 grant [WEB ESTIMATE — BiopharmaWatch reproduction of the GlobeNewswire release, 2026-10-14] |
| Partnerships and licences | (1) ABL Bio, November 2018: tovecimig in-licence, terms in C.1; ABL Bio has received $5 million upfront and a $6 million milestone. (2) Handok: holds South Korea. (3) Elpiscience: China out-licence; paid a $1 million milestone in 2024, of which 15% passes to ABL Bio. (4) Adimab, 2014: antibody discovery, single-digit royalties. (5) Investigator-sponsored trials at MD Anderson (first-line BTC) and Washington University (colorectal, glioblastoma). No partner shares tovecimig’s US economics. | [VERIFIED — Form 10-K for 2025; Form 10-Q filed 2026-08-06] |
C.2 Pipeline — every program
Every row returned by fetch_company_drugs on 2026-10-17 is listed. “Date to a day?” is yes only
where catalyst_date_text names a day (01-rules.md rule 23). Every “no” row carries a BPIQ
period-end placeholder in catalyst_date. No timing anywhere in this repository uses it.
| Program (drug — indication) | bpiq_drug_id | Stage & event | Catalyst (as disclosed) | Date to a day? | Analysed? | Materiality to the stock |
|---|---|---|---|---|---|---|
| Tovecimig (CTX-009), DLL4 × VEGF-A bispecific antibody — biliary tract cancer | 17398 | Phase 2/3 Data readout | ”October 24, 2026” | Yes | Yes — tovecimig-biliary-tract-cancer/ | Dominant. The only late-stage asset and the only planned marketing application. Its two 2026 events produced the two largest moves in C.7 (−64.6% and −35.2% over the protocol’s event window). With the shares at the cash floor (C.4), any re-rating of the company runs through this program. |
| Tovecimig (CTX-009) — colorectal cancer | 17399 | Phase 2 Update | ”TBA” | No | No | Immaterial. has_catalyst is false. COMPANION-003 did not advance in November 2024. The row now tracks an investigator-sponsored Phase 2 (NCT07662031, Washington University, 25 patients) that the 2026-08-06 release says has been initiated. Nothing datable. |
| Tovecimig + CTX-471 — glioblastoma | 20762 | Phase 2 Initiation | ”TBA” | No | No | Immaterial. has_catalyst is false. An investigator-sponsored Phase 1b/2 (NCT07392957, 54 patients) with a 2029 primary completion date. |
| CTX-471 ± pembrolizumab (KEYTRUDA) — NCAM-positive tumours | 17478 | Phase 2 Initiation | ”Q3 2026” | No | No | Immaterial. has_catalyst is false. A trial start, not data. The Q3 2026 date has passed with no start announced, and NCT07684170 is registered as not yet recruiting. |
| CTX-8371, PD-1 × PD-L1 bispecific antibody — solid tumours | 17481 | Phase 1 Data readout | ”Q4 2026” | No | No | Meaningful. Expansion-cohort data are guided for Q4 2026 after an ASCO 2026 poster with responses and no dose-limiting toxicities. With tovecimig’s filing in doubt, a larger share of the remaining value sits here. Its “Q4 2026” window covers tovecimig’s disclosed day, so it is one of the two conflicts that make that program CONTAMINATED. |
| CTX-10726, PD-1 × VEGF-A bispecific antibody — solid tumours | 18722 | Phase 1 Data readout | ”Q4 2026” | No | No | Meaningful but speculative. First patients were dosed in 2026 (NCT07419841, started 2026-05-28). Initial data are guided for Q4 2026. PD-1 × VEGF bispecifics are a crowded and fashionable class, which makes a signal valuable and a thin one easy to dismiss. The second conflict inside the tovecimig window. |
Three rows carry has_catalyst: true and all three fall in the fourth quarter of 2026. One of
the three dates is disclosed to a day. So the collision the program document’s Attribution section
describes is a real feature of this pipeline, not two placeholders touching.
C.3 Financial position
| Item | Value | As of | Tag |
|---|---|---|---|
| Cash and equivalents | $35.453M of cash and equivalents; $179.879M with marketable securities ($144.426M) | 2026-06-30 | [VERIFIED — EDGAR XBRL CashAndCashEquivalentsAtCarryingValue and MarketableSecuritiesCurrent, 10-Q filed 2026-08-06] |
| Burn (per month) | $4.913M (second quarter); $5.335M (first-half average) | quarter to 2026-06-30 | [VERIFIED — EDGAR XBRL NetCashProvidedByUsedInOperatingActivities: −$32.007M for the half, −$17.269M for the first quarter, so −$14.738M for the second] |
| Runway as the company states it | ”into 2028” | 2026-08-06 | [VERIFIED — Form 10-Q filed 2026-08-06]. Not restated after the FDA feedback: the 2026-09-22 8-K gives no runway. |
| Runway recomputed (cash ÷ burn) | 36.6 months, to about mid-2029 | 2026-06-30 | [UNVERIFIED — computed] $179.879M ÷ $4.913M a month |
| Debt | None | 2026-06-30 | [VERIFIED — EDGAR XBRL companyfacts: no debt concept reported; total liabilities $24.124M, mostly accrued expenses and an office lease] |
The company’s runway is the one to use, as in the 5.10.3 version. “Into 2028” implies a burn well above the second-quarter rate, which fits a company building toward a launch. The FDA recommendation may change that plan in either direction: a survival trial costs money, while a delayed launch saves commercial spending. The company has not said which. BPIQ’s screening text once carried a runway to 2029-01-08. It is empty this sweep and was never used.
Dilution history.
| Date | Instrument | Gross proceeds | Price | Source |
|---|---|---|---|---|
| 2025-08-12 | Underwritten public offering: 33,290,000 shares and 6,710,000 pre-funded warrants (warrants paid for upfront, exercisable at $0.0001), plus 6,000,000 option shares the underwriters bought | $138.0M ($120.0M base plus $18.0M option) | $3.00 a share; $2.9999 a pre-funded warrant | [VERIFIED — Form 10-Q filed 2026-08-06, equity note; 424B5 filings 2025-08-12 and 2025-08-13] |
| 2025-12-30 | Form S-3 shelf of up to $400M, including an at-the-market (ATM) programme of up to $100M with Leerink Partners and Cantor Fitzgerald. An ATM sells new shares gradually into the market. | Nil to 2026-06-30: “we did not sell any shares” | n/a | [VERIFIED — S-3 filed 2025-12-30, EFFECT 2026-01-07; Form 10-Q filed 2026-08-06] |
| 2026-03-12 | Form S-8 (registers shares for employee plans) | Nil, not a raise | n/a | [VERIFIED — EDGAR submissions] |
No offering was announced and then withdrawn. Named correction: the 5.10.3 version put the August 2025 raise at $120M and derived an implied $3.03 a share. The 10-Q shows $138.0M gross at $3.00, because the underwriters also bought 6,000,000 option shares.
A raise before the 2026-10-24 presentation is unlikely. Selling shares at about cash value would dilute holders for little money. The ATM capacity is unused and the public float is worth about $136M, above the $75M line below which the SEC limits shelf sales. So a sale is possible at any time after the event, and most likely into any strength it produces.
C.4 Valuation frame
| Item | Value | Source / tag |
|---|---|---|
| Share price (spot) | $0.86, the settled close of Friday 2026-10-16 | [VERIFIED — data/prices/CMPX.json via lib/prices.mjs closeOnOrBefore, fetched 2026-10-17 after the close; matches BPIQ last_price 0.86 and Yahoo's daily close] |
| Market capitalisation | $154.9M | [UNVERIFIED — computed] 180,087,915 filed shares × $0.86. BPIQ’s $154,875,616 agrees. |
| Enterprise value | −$25.0M against 2026-06-30 cash; about −$10.3M against an estimated 2026-09-30 cash of $165.1M | [UNVERIFIED — computed] $154.9M − $179.879M; the 2026-09-30 cash is extrapolated at the second-quarter burn and is not reported. BPIQ’s $40,456,860 is not used (C.8 row 2). |
| 52-week high / low | $6.88 (2026-02-03) / $0.822 (2026-10-14) | [VERIFIED — data/prices/CMPX.json, lib/prices.mjs range52w as of 2026-10-16] |
| Position in the 52-week range, computed off the last price | 0.6% | [UNVERIFIED — computed] lib/prices.mjs positionInRange(0.86, 0.822, 6.88) = 0.00627. BPIQ’s 0.00627 agrees. |
| Multiple off the 52-week low | 1.05× | [UNVERIFIED — computed] $0.86 ÷ $0.822 |
| Economic share count | 186,797,915 | [VERIFIED — XBRL dei:EntityCommonStockSharesOutstanding 180,087,915 at 2026-07-28, plus 6,710,000 pre-funded warrants outstanding per the 10-Q filed 2026-08-06] |
This row is the run-up baseline for every program under this ticker. The shares sit at the bottom of a range whose top was set on 2026-02-03, before both 2026 tovecimig events. They closed below $1 on 11 of the 12 sessions since 2026-10-01. Only 2026-10-07 ($1.02) closed above.
Listing compliance, and why it does not touch the per-share figures. Nasdaq gives notice of a
deficiency after 30 consecutive business days with a closing bid below $1.00 (Listing Rule
5550(a)(2)). The company then has 180 days to recover, often followed by a reverse split, which
merges shares and multiplies the price [UNVERIFIED — rule summary, not read from the rulebook this sweep]. The current run began on 2026-10-08: seven business days by 2026-10-16. So no notice can
arrive before about 2026-11-19, and no notice is on EDGAR. The June 2026 annual meeting voted on
directors, the auditor and pay only [VERIFIED — 8-K filed 2026-06-11, item 5.07]. No reverse
split is authorised, so none can land inside this event’s settlement window. Every per-share
figure here is on the current share count.
Economic share count. Common shares (180,087,915) plus pre-funded warrants (6,710,000) gives
186,797,915. No warrant or option is in the money at $0.86. The 23,650,088 options outstanding at
2026-06-30 carry a weighted average exercise price of $3.87, and the 200,000 options of
2026-10-14 were struck at $0.86 itself [VERIFIED — XBRL companyfacts; 10-Q filed 2026-08-06].
The 1,606,250 unvested restricted stock units are not options and are left out, as the rule
defines the count. Named correction: the 5.10.3 version divided its cash per share by the
reported 180,087,915 shares and missed the pre-funded warrants.
C.5 Ownership and flow
| Holder type | Share | Note | Source |
|---|---|---|---|
| Insider | 12.47% | Includes the OrbiMed / Carl Gordon 10%-owner position, reported both as a fund and as a director | [VERIFIED — BPIQ fetch_company_info 2026-10-17, insider_own 0.12467] |
| Institutional | 88.56% | Overlaps the insider figure; the two are not additive | [VERIFIED — BPIQ fetch_company_info 2026-10-17, tute_own 0.88559] |
| Retail / other | Not separately reported | The two figures above sum above 100%, so no residual can be derived | [UNVERIFIED] |
| Short interest | 40,357,710 shares = 22.4% of shares outstanding, or 25.6% of the estimated non-affiliate float (157.6M shares); days-to-cover 6.26 | Settlement 2026-09-30. It peaked at 41,647,512 on 2026-09-15 and eased 3.1% after the FDA news. | [VERIFIED — FINRA consolidatedShortInterest, settlement 2026-09-30, divided by the EDGAR-filed share count] |
Short interest by settlement [VERIFIED — FINRA consolidatedShortInterest, read 2026-10-17]:
| Settlement | Shares short | Average daily volume | Days to cover |
|---|---|---|---|
| 2026-07-31 | 39,874,250 | 2,263,276 | 17.62 |
| 2026-08-14 | 40,197,938 | 4,110,600 | 9.78 |
| 2026-08-31 | 40,788,891 | 2,362,777 | 17.26 |
| 2026-09-15 | 41,647,512 | 2,605,174 | 15.99 |
| 2026-09-30 | 40,357,710 | 6,449,901 | 6.26 |
Days to cover fell because volume tripled after the FDA news, not because shorts closed. The short count barely moved.
Insider flow: the first open-market buying since April, and it is small. The chief accounting
officer, Neil Lerner, bought 2,500 shares at $1.14 on 2026-09-24 and 20,000 shares at $0.92 on
2026-10-01. Both are transaction code P, an open-market purchase. Together they cost about $21,250
and took his holding to 420,000 shares, of which 62,500 are unvested restricted stock units
[VERIFIED — EDGAR Form 4s filed 2026-09-25 and 2026-10-02]. No other officer or director has
filed a Form 4 since 2026-04-30. One officer buying a small amount is a gesture. The silence of
every other insider at about cash value is the larger fact.
Concentration is high, and no new register is visible yet. The newest 13F block (the quarterly
filing in which large funds disclose holdings) is labelled 2026Q3 and holds positions at
2026-06-30. It is the same block the last sweep read. The six funds in it are Tang Capital
(17.99M shares), OrbiMed (15.22M), Vivo (7.76M), Palo Alto Investors (5.83M), ADAR1 (0.12M) and
Ikarian (18,000) [VERIFIED — BPIQ fetch_company_hedge_fund_holdings 2026-10-17, share counts].
Together they hold about 46.9M shares, roughly a quarter of the company. How they traded through
the 2026-09-22 news will show in 13Fs due by 2026-11-14. EDGAR also shows a State Street Schedule
13G (a filing by a passive holder of more than 5%) dated 2026-08-07, reported at 9.95M shares
[WEB ESTIMATE — Stock Titan summary of the 13G, 2026-08-11].
The law-firm “investigation” announcements of April to July 2026 were not followed by any filed
complaint visible in EDGAR or the press feed [VERIFIED — EDGAR submissions and press feed, 2026-10-17].
C.6 Options chain and its readability
Plain takeaway: the chain cannot price this event. No strike sits at the $0.86 spot. The nearest are $0.50 and $1.00, and the quotes around them are too wide to read a price from. Two positions stand out. An open interest of 60,014 contracts sits on the January 2027 $1.00 put, which covers about 6 million shares. And 23,664 contracts of the November $3.00 call remain from the August speculation, now far out of the money. Neither says what the market expects from the 2026-10-24 presentation.
| Item | Value | Note |
|---|---|---|
| Spot | $0.86 | C.4 |
| Nearest listed strike to spot | $0.50 below, $1.00 above; nothing between | The $1.00 strike sits 16% above spot. |
| Expiry nearest the next catalyst | 2026-11-20, the first expiry after the 2026-10-24 presentation | The 2026-10-16 expiry has passed. |
| At-the-money straddle ÷ spot | Not computable | A straddle (a call and a put at the strike nearest spot) can only be bracketed at $1.00 on the 2026-11-20 expiry. At mid prices it costs $0.45, or 52% of spot. The bid side gives $0.25 (29%) and the ask side $0.65 (76%). A range that wide is not a price. |
| Front implied volatility | 2.53 ($1.00 call) and 1.24 ($1.00 put), 2026-11-20 expiry | Both are off the BPIQ floor (~0.01488) and ceiling (~9.99512) artifacts. Several other strikes sit on one artifact or the other and are treated as missing. The call and put at the same strike disagree by a factor of two, which says the quotes are not trading prices. |
| Open interest at that strike | $1.00 call 2,700; $1.00 put 1,334 (2026-11-20) | 5,385 of the $1.00 calls traded in the last session. |
| Liquidity confidence | Low | No strike at spot, spreads of 100% or more, and contradictory implied volatility. |
The program document therefore takes its move range from the ticker’s own history and a stated calibration, not from this chain.
C.7 Reaction to past catalysts
How to read the two move columns. The BPIQ columns are the connector’s own fields. The
event-window column is computed from the price cache with the window 05-prediction-protocol.md
uses at settlement: the average of the two closes before the announcement day, against the average
of the announcement-day close and the next day’s close. The cache did not exist at the last sweep.
It now shows that several BPIQ figures cannot be reproduced (C.8 row 3). The event-window column
is the one the program document’s anchors read.
| Date | Event | BPIQ intraday / open gap | Event window (cache) | Same-day press-feed check | Read |
|---|---|---|---|---|---|
| 2026-09-22 | FDA recommended a trial showing a survival benefit before a BLA for tovecimig in previously treated biliary tract cancer | −0.80% / −31.32% | −35.2% (close to close −31.9%, $1.82 → $1.24, on 27.2M shares, about eleven times normal volume) | The company’s release the same morning (8-K exhibit 99.1). The next day, Wedbush cut to Neutral with a $1 target (from $5), and other brokers cut too. No offering, no other program news. | A regulatory event, and clean. The gap is the move, as on 2026-04-27. The shares kept falling for nine more sessions, to $0.857 on 2026-10-02, and have stayed below $1 since. |
| 2026-04-27 | COMPANION-002 secondary endpoints: progression-free survival met (4.7 vs 2.6 months, hazard ratio 0.44); overall survival not met (8.9 vs 9.4 months, hazard ratio 1.05) | +1.13% / −64.81% | −64.6% (close to close −64.4%, $5.03 → $1.79, on 159.0M shares) | Six same-day items describing a collapse, plus two law-firm solicitations | The gap is the move; the intraday figure is not. Kept from the 5.10.3 version, and now confirmed by the cache. The market punished a secondary-endpoint miss on a trial whose primary endpoint had already been met. |
| 2025-04-21 | First patient dosed in an investigator-sponsored first-line trial | +8.72% / −1.71% | +9.0% (close to close +1.7%) | The announcement itself | Administrative. More plausibly drift from the weeks after 2025-04-01 than a reaction to the dosing. |
| 2025-04-01 | COMPANION-002 met its primary endpoint (overall response rate) | +49.73% / −1.58% | +1.0% (close to close +17.9%, $1.90 → $2.24; the next day fell to $1.69) | Two same-day items, both the endpoint announcement | Named correction. The 5.10.3 version read the +49.73% as “roughly doubled the shares” and used it as the upper bound for tovecimig news. The cache shows a day that opened at $1.87, fell to $1.33 and closed at $2.24. The +49.73% matches none of the cache’s open-to-close (+19.8%), close-to-close (+17.9%) or low-to-close (+68.4%) moves for that day. Over the event window the hit was worth +1.0%, because the next session gave the gain back. |
| 2024-11-08 | CTX-471 Phase 1 biomarker data at the Society for Immunotherapy of Cancer meeting | +4.28% / +1.63% | +0.8% (close to close −2.2%) | The announcement itself | The nearest comparable in kind to the 2026-10-24 event: a congress presentation of data already described. Over the window it moved +0.8%. The BPIQ figure does not reproduce. |
| 2024-08-12 | COMPANION-003 colorectal Phase 2 data, released with second-quarter results | +7.14% / +2.75% | +11.0% (close to close +3.7%) | The same-day earnings release carried the data | Bundled with earnings, so not cleanly attributable. |
| 2024-04-16 | First patient dosed, CTX-8371 Phase 1 | +8.86% / 0.00% | −3.1% (close to close −0.6%) | The announcement itself | Administrative. |
| 2024-04-09 | Preclinical CTX-009 + CTX-471 data at the American Association for Cancer Research meeting | +8.28% / −0.59% | −3.8% (close to close −1.8%) | A third-party (Synapse) summary, not a company release | Preclinical. Recorded for completeness. |
What the table says as a whole. Read from the cache, this ticker’s data events in 2024–2025 moved it very little over the event window: +1.0%, +0.8% and +11.0% on its positive data rows. Its two 2026 tovecimig events were hypothesis-level news (a survival endpoint and an FDA position), and each removed a third to two-thirds of the price. The 2026-10-24 event is a presentation of data whose headline figures are already public. The 5.10.3 version drew the same distinction. It also leaned on a +49.7% upside figure that the cache now shows was never a two-day move.
C.8 Company data-quality flags
market_capandmax_52_week_positionreconcile on this sweep, and the earlier failure is kept as history. On 2026-08-19 both fields were computed off the previous close (5.10.3 C.8 rows 1 and 2). On 2026-10-17, a Saturday,last_priceequals the last close. BPIQ’s $154,875,616 equals 180,087,915 × $0.86, and its 0.00627 equals the cache’s position. The bug cannot be seen when the last price and the last close are the same price, so this sweep does not show it was fixed.enterprise_valuecannot be reconciled. BPIQ’s $40,456,860 against its own $154,875,616 market cap implies subtracting $114.4M. Its owncashfield is $179.879M. No reported cash figure at any recent quarter-end is $114.4M (2025-12-31: $208.9M; 2026-03-31: $194.7M; 2026-06-30: $179.9M). C.4 recomputes.- BPIQ’s historical-catalyst move fields do not reproduce from the price cache on most CMPX
rows. The 2025-04-01 row’s +49.73% “intraday” figure matches no open-to-close,
close-to-close or low-to-close move in the cache. The 2024-11-08 row’s +4.28% sits against a cache day that
closed below its open. The rows created on 2025-02-21 all carry
news_published_at2025-02-15, which suggests their price fields were computed from a different day. C.7 shows the BPIQ figures beside the cache’s event-window figures and uses the cache. - The price cache froze an intraday bar on 2026-08-19, the day of the last lock. The stored
bar reads close $2.42 on 1,160,393 shares. Yahoo’s daily chart gives a settled close of $2.48
on 3,903,300 shares (checked 2026-10-17). This is the failure
scripts/fetch-prices.mjsis known for: it never overwrites a bar first written mid-session. The 5.10.3 record’s spot of $2.48 matches the settled close. The cache does not.data/prices/is outside this analysis’s lane, so the bar is reported here and not corrected. The 2026-10-16 bar this lock uses ($0.86 on 2,038,900 shares) matches Yahoo’s settled figures. fetch_company_insider_transactionsreturned zero rows on three attempts while two Form 4s exist. This is the connector-wide bug02-connectors.mddocuments. It is now confirmed on a third ticker, and on a ticker where the same call had worked eight weeks earlier. C.5 reads the flow from EDGAR.- 13F block labels are filing quarters on this ticker, now confirmed against the cache. Value ÷ shares gives $2.19 for the 2026Q3 block, $5.29 for 2026Q2 and $5.37 for 2026Q1. Those equal the cache closes of 2026-06-30 ($2.19), 2026-03-31 ($5.29) and 2025-12-31 ($5.37). Each block holds positions one quarter older than its label. The 5.10.3 version reached this from the implied prices alone, because the cache did not exist then.
short_floatdisagrees with FINRA, and the 5.10.3 explanation is withdrawn. BPIQ reports 0.30476, dated 2026-09-30. FINRA’s 2026-09-30 count is 22.4% of shares outstanding or 25.6% of the non-affiliate float. The 5.10.3 version suggested a rising count might explain BPIQ’s 0.30106 at 2026-07-31. FINRA’s 2026-07-31 settlement, readable this sweep, shows 39,874,250 shares, 22.1% of shares outstanding. So rising short interest does not explain the gap. BPIQ’s figure implies a denominator of about 132M shares, which matches no float this sweep can derive.- The
notefield is a dated slip log on four of six rows. CTX-471’s Phase 2 start has now missed five guided dates. The tovecimig row’s slips are counted in the program document. - A “Revenue ($25.25M)” figure circulates in third-party summaries of the second-quarter 10-Q,
and it stays rejected under
01-rules.mdrule 6. Kept from 5.10.3. Compass has no product. The 10-Q’s quarterly net loss is $25.154M, and the summariser mislabelled a loss line as revenue. - Analyst targets conflict, and none is an anchor under 6.2.0. Kept from 5.10.3: one
aggregator’s $14.57 average and $30 high were stale pre-April targets. After 2026-09-22,
Wedbush moved to $1 from $5, Guggenheim to $4 and H.C. Wainwright to $12 from $24
[WEB ESTIMATE — Seeking Alpha, MarketScreener and Stocktwits coverage, 2026-09-23].01-rules.mdrule 30 bars analyst targets from scenario anchors. They are recorded here so that a reader who meets them knows they were seen. - Two GlobeNewswire originals returned HTTP 403 to a direct fetch (2026-09-22 and 2026-10-14). The first was read from its SEC copy. The second, the 200,000-option inducement grant, rests on a secondary reproduction only.